BioNTech's Pipeline Delivers in Seoul While the C-Suite Prepares for a Handover

BioNTech's gotistobart nearly doubled median survival in a Phase 3 lung cancer trial, but a guidance cut and CEO succession keep the story two-sided.

For a company long defined by its COVID-19 vaccine franchise, BioNTech is quietly assembling a different kind of story — one told in survival curves rather than dose orders. The Mainz-based biotech used the IASLC World Conference on Lung Cancer, held September 12–15 in Seoul, to put hard Phase 3 numbers behind that narrative, even as a leadership transition and a softening revenue outlook keep the investment case genuinely two-sided.

Gotistobart nearly doubles median survival

The headline readout came from PRESERVE-003, a Phase 3 trial of gotistobart — an antibody developed with partner OncoC4 — in previously treated squamous non-small cell lung cancer. Patients on the drug achieved a median overall survival of 18.5 months, compared with 10.0 months for those receiving standard chemotherapy.

At a July data cut with 25.4 months of median follow-up, the hazard ratio stood at 0.56, with a nominal p-value of 0.0295. Whatever the market does with that figure, it represents a clinically meaningful result in an indication where options are thin. BioNTech also rolled out first global data in Seoul on pumitamig combined with elfetabart drozuntecan in advanced small cell and non-small cell lung cancer, broadening the evidence base beyond a single asset.

The shares responded in kind, climbing 2.9% to EUR 86.10 on the day the survival data landed.

A setback in August that set the tone

The Seoul presentations did not arrive in a vacuum. On August 29, BioNTech disclosed the termination of a Phase 2 study of autogene cevumeran, an experimental mRNA cancer vaccine. An independent monitoring committee had concluded the treatment was unlikely to extend survival in colorectal cancer patients. Reuters reported the stock fell 7.5% on the US exchange following the announcement.

That disappointment rippled into analyst sentiment. On September 8, BMO Capital Markets downgraded the stock from Outperform to Market Perform and cut its price target from USD 128 to USD 105 — the most recent documented rating change from a major house in this window.

Guidance cut still weighs on the tape

Lingering beneath the clinical headlines is a revenue picture that has been trimmed. BioNTech now expects 2026 revenue of just EUR 1.6 billion to EUR 1.9 billion, down from a prior range of EUR 2.0 billion to EUR 2.3 billion — a revision the company attributes to weaker global demand for COVID-19 vaccines and the absence of milestone payments. The second quarter delivered a net loss of EUR 820.8 million on revenue of just EUR 105.6 million.

None of this is fresh news, but it explains why strong oncology data has not translated into a sustained breakout. Over the past 30 days, the stock has nonetheless gained 8.2%, suggesting the market is at least partially pricing in the pipeline shift.

Insider sales: routine mechanics, awkward timing

Adding texture to the story are repeated share sales by CEO Ugur Sahin — most recently on September 14, before that on September 11, and on September 10, when a package of 20,500 shares changed hands at an average of USD 96.31, worth roughly USD 1.97 million.

The transactions are executed under a pre-arranged Rule 10b5-1 trading plan, which makes them legally routine and mechanically automated rather than a spontaneous signal from management. Still, the clustering deserves a mention: the supervisory board already settled the succession question in August, with Guido Oelkers slated to take over as CEO no later than February 1, 2027, replacing Sahin. A departing chief executive steadily unwinding a position is not, on its own, an alarm bell — but the frequency since early September is worth watching.

Where the story stands

BioNTech today looks like a company mid-transformation. The original vaccine business continues to fade, while the oncology pipeline — gotistobart, pumitamig, and the combination programs presented in Seoul — increasingly carries the substance of the equity story. The clinical progress currently outweighs the near-term drags, though the real test will be whether those Phase 3 results convert into commercial traction in the quarters ahead.